https://orcid.org/0000-0002-0957-4903
References
- World health Organization. Global tuberculosis report 2020. https://www.who.int/publications/i/item/9789240013131. Accessed May 10, 2022.
- Pradhan S, Madke B, Neema S, Kabra P, Singh AL, Yadav S. Screening of latent tuberculous infection (LTBI) before starting anti-tumor necrosis factor therapy in patients with psoriasis: a primer for clinical dermatologist. Indian J Dermatol. 2021;66:501–507.
- Puig L, Tsai TF, Bhutani T, et al. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled Phase 3 VOYAGE 1 & VOYAGE 2 trials. J Eur Acad Dermatol Venereol. 2020;34(8):1744–1749. doi:10.1111/jdv.16460
- Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43–53. doi:10.1016/j.jaad.2018.06.056
- Nogueira M, Warren RB, Torres T. Risk of tuberculosis reactivation with interleukin (IL)-17 and IL-23 inhibitors in psoriasis - time for a paradigm change. J Eur Acad Dermatol Venereol. 2021;35:824–834. doi:10.1111/jdv.16866
- Elewski BE, Baddley JW, Deodhar AA, et al. Association of secukinumab treatment with tuberculosis reactivation in patients with psoriasis, psoriatic arthritis, or ankylosing spondylitis. JAMA Dermatol. 2021;157(1):43–51. doi:10.1001/jamadermatol.2020.3257
- Khanna U, Gallop J, Ellis A, et al. Routine rescreening for latent tuberculosis has low utility in patients with chronic immune-mediated inflammatory diseases treated with biologics: a single-center, retrospective cohort study. J Am Acad Dermatol. 2022;87:841–843. doi:10.1016/j.jaad.2022.05.027